Now showing items 1-2 of 2

    • CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair. 

      Shenoy, TR; Boysen, G; Wang, MY; Xu, QZ; Guo, W; Koh, FM; Wang, C; Zhang, LZ; Wang, Y; Gil, V; Aziz, S; Christova, R; Rodrigues, DN; Crespo, M; Rescigno, P; Tunariu, N; Riisnaes, R; Zafeiriou, Z; Flohr, P; Yuan, W; Knight, E; Swain, A; Ramalho-Santos, M; Xu, DY; de Bono, J; Wu, H (2017-07)
      Background:Deletion of the chromatin remodeler chromodomain helicase DNA-binding protein 1 (CHD1) is a common genomic alteration found in human prostate cancers (PCas). CHD1 loss represents a distinct PCa subtype characterized ...
    • SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. 

      Boysen, G; Rodrigues, DN; Rescigno, P; Seed, G; Dolling, D; Riisnaes, R; Crespo, M; Zafeiriou, Z; Sumanasuriya, S; Bianchini, D; Hunt, J; Moloney, D; Perez-Lopez, R; Tunariu, N; Miranda, S; Figueiredo, I; Ferreira, A; Christova, R; Gil, V; Aziz, S; Bertan, C; de Oliveira, FM; Atkin, M; Clarke, M; Goodall, J; Sharp, A; MacDonald, T; Rubin, MA; Yuan, W; Barbieri, CE; Carreira, S; Mateo, J; de Bono, JS (2018-11)
      Purpose: CHD1 deletions and SPOP mutations frequently cooccur in prostate cancer with lower frequencies reported in castration-resistant prostate cancer (CRPC). We monitored CHD1 expression during disease progression and ...